

JUL. 16. 2004 2:48PM AVENTIS US PAT DEPT  
TO: US CENTRALIZED USPTO

NO. 5434 P. 1

RECEIVED

CENTRAL FAX CENTER

JUL 16 2004

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:  
**FRAV2002/0020USNP**

Applicants:  
**CORTI, et al.**

Serial No.  
**10/622,817**

Filing Date:  
**July 18, 2003**

Title of Invention:

**METHOD FOR DETERMING THE ABILITY OF A COMPOUND TO MODIFY THE INTERACTION  
BETWEEN PARKIN AND THE p38 PROTEIN**

**CERTIFICATE OF TRANSMISSION**  
I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, Patent Application, at 703-872-9306, on  
Date of Deposit July 16, 2004  
Printed Name of Person Signing Certificate Delia Coughlin  
Signature Delia Coughlin

Total Number of Pages Sent: 3

Attorney: Karen I. Krupen  
Reg. No. 34,647  
Group Art Unit: 1614  
Examiner: Not Yet Known

OFFICIAL

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Fee Transmittal
<input type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Extension of Time Petition	<input checked="" type="checkbox"/> Other <u>Submission of Power of Attorney</u> <u>Aventis Pharma S.A.</u>
<input type="checkbox"/> Issue Fee Transmittal & Advance Order	<input checked="" type="checkbox"/> Other <u>Submission of Power of Attorney</u> <u>Institut National De La Sante</u> <u>Et De La Recherche Medicale</u>
<input type="checkbox"/> Maintenance Fee Transmittal	

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telexcopy transmission are intended only for the use of the individual or entity named above. If you have received this telexcopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

Aventis Docket No. FRAV2002/0020 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: CORTI, et al.

Examiner: Not Yet Known

Serial No.: 10/622,817

Group Art Unit.: Not Yet Known

Filed: July 18, 2003

RECEIVED  
CENTRAL FAX CENTERTitle: METHOD FOR DETERMINING THE ABILITY  
OF A COMPOUND TO MODIFY THE  
INTERACTION BETWEEN PARKIN AND THE  
p38 PROTEIN

JUL 16 2004

OFFICIAL

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Patent Application  
 Commissioner for Patents  
 P. O. Box 1450  
 Alexandria, VA 22313-1450

I, BOUVET Philippe, an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: July 18, 2003

By:

BOUVET Philippe

Title: ExecutiveDate: March 8, 2004

Address correspondence and telephone calls to:  
 Michael Schmelzer, Reg. No. 43,093  
 Aventis Pharmaceuticals Inc.  
 Patent Department  
 Route #202-206 / P.O. Box 6800  
 Bridgewater, New Jersey 08807-0800  
 Telephone (908) 231-4797  
 Telefax (908) 231-2626

Aventis Docket No. FRAV2002/0020USNP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: CORTI, et al.

Examiner: To Be Assigned

Serial No.: 10/622,817

Group Art Unit: Unknown

Filed: July 18, 2003

**Title: METHOD FOR DETERMINING THE ABILITY OF  
A COMPOUND TO MODIFY THE INTERACTION  
BETWEEN PARKIN AND THE p38 PROTEIN****POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I, Christine BERLING, an Authorized Signatory of Institut National De La Sante Et De La Recherche Medicale, Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: July 18, 2003  
By: Christine BERLING / INSTITUT NATIONAL DE SANTE  
et de la RECHERCHE MEDICALE  
Directrice Adjointe  
Département Valorisation / 101, AVENUE VERSAILLES  
et Transfert de Technologies 75031 PARIS CEDEX 13

Title: Pour le Directeur Général et par déléction  
Date: 16 MAI 2004

Address correspondence and telephone calls to:  
Michael J. Schmelzer, Reg. No. 43,093  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4797  
Telefax (908) 231-2626